Dr Debashis Sarker Academics Supervisors Senior Lecturer and Consultant in Medical Oncology Contact details debashis.sarker@kcl.ac.uk
Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., Meyer, T., Huang, K. W., Plummer, R., Chee, C. E., Spalding, D., Pai, M., Khan, S., Pinato, D. J., Sharma, R., Basu, B. & 11 others, Palmer, D., Ma, Y. T., Evans, J., Habib, R., Martirosyan, A., Elasri, N., Reynaud, A., Rossi, J. J., Cobbold, M., Habib, N. A. & Gabrilovich, D. I., 15 Nov 2021, In: Clinical Cancer Research. 27, 21, p. 5961-5978 18 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1158/1078-0432.CCR-21-0986 A phase I, open-label, dose-finding study of GSK2636771, a PI3Kb inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer Sarker, D., Dawson, N. A., Aparicio, A. M., Dorff, T. B., Pantuck, A. J., Vaishampayan, U. N., Henson, L., Vasist, L., Roy-Ghanta, S., Gorczyca, M., York, W., Ganji, G., Tolson, J. & de Bono, J. S., 1 Oct 2021, In: Clinical Cancer Research. 27, 19, p. 5248-5257 10 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1158/1078-0432.CCR-21-1115 Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation-Results from the MACPIE-I study Kundalia, K., Hakeem, A., Papoulas, M., Mcphail, M., Reddy, S., Peddu, P., Kibriya, N., Atkinson, S., Prachalias, A., Srinivasan, P., Heaton, N., Sarker, D., Ross, P., Zen, Y. & Menon, K., Oct 2021, In: European Journal of Surgical Oncology. 47, 10, p. 2571-2578 8 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.ejso.2021.05.024 Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C. C., Godbert, Y., Sarker, D. & 5 others, Miller, S. G., Clifford, C., Zhang, H., Turner, C. D. & Taylor, M. H., Aug 2021, In: The Lancet Diabetes and Endocrinology. 9, 8, p. 491-501 11 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/S2213-8587(21)00120-0 Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts Pfeifer, E., Burchell, J. M., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 7, 1653. Research output: Contribution to journal › Review article › peer-review. DOIs: https://doi.org/10.3390/cells10071653 Apoptosis in the Pancreatic Cancer TumorMicroenvironment— The Double-Edged Sword of Cancer-Associated Fibroblasts Pfeifer, E., Burchell, J., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 1653, 18 p. Research output: Contribution to journal › Review article › peer-review Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison Trojan, J., Mollon, P., Daniele, B., Marteau, F., Martín, L., Li, Y., Xu, Q., Piscaglia, F., Zaucha, R., Sarker, D., Lim, H. Y. & Venerito, M., May 2021, In: ADVANCES IN THERAPY. 38, 5, p. 2472-2490 19 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1007/s12325-021-01700-2 Pancreatic cancer exposome profile to aid early detection and inform prevention strategies Monroy-Iglesias, M. J., Dolly, S., Sarker, D., Thillai, K., Van Hemelrijck, M. & Santaolalla, A., Apr 2021, In: Journal of Clinical Medicine. 10, 8, 1665. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.3390/jcm10081665 Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer Sarker, D., 1 Dec 2020, In: Nature Communications. 11, 1, 4841. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1038/s41467-020-18636-w The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy Webb, T. E., Davies, M., Maher, J. & Sarker, D., 1 Sep 2020, In: Clinical and Translational Radiation Oncology. 24, p. 123-126 4 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.ctro.2020.07.002 View all publications